Loading…
← CockpitCompetitor Analysis › 301017.SZ Shu Yu Civilian Pharmacy Corp., Ltd. Class AOpen in the cockpit ↗

Shu Yu Civilian Pharmacy Corp., Ltd. Class A301017.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Drugstore Chains
Momentum neutral 59
Mkt cap
$701M
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$18.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+1.2 pp
WACC 5.4%
Hurdle
-16 pp
Req g minus delivered
Next earnings
168 days
5 May 2027
Close · CNYCN¥11.92
1D-6.9%
1W-17.8%
1M-16.8%
3M-14.8%
6M-11.2%
YTD-19.2%
1Y-4.5%
ATR %6.6%
52w lowhigh48.2% off high

What Shu Yu Civilian Pharmacy does

Employees: 15,933

Shu Yu Civilian Pharmacy at a glance

Size Shu Yu Civilian Pharmacy (301017.SZ) is a China Consumer Staples company (Drugstore Chains) with a market value of $701M, the 2898th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.92 on 18 Nov 2026.

Performance Over six months the shares fell 11.2%, against -10.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 15 in its peer set.

Growth Revenue grew 9.2% over the last twelve months (peer median +3.9%); the operating margin is 1.9% (peer median 4.3%).

Valuation It trades at 0.8× enterprise value to sales against a peer median of 0.7× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.2 points above its cost of capital (5.4% WACC).

Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 90301017.SZ 88
Six months, rebased to 100: Shu Yu Civilian Pharmacy against the median of its 14 peers (local-currency closes).

Shu Yu Civilian Pharmacy financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥10.9BCN¥10.3BCN¥9.55BCN¥9.17BCN¥7.81B
Revenue growth—+8%+4%+17%—
Gross profitCN¥3.11BCN¥2.62BCN¥2.32BCN¥2.50BCN¥2.16B
EBITDAn/aCN¥616MCN¥571MCN¥854MCN¥800M
Net incomeCN¥26.9MCN¥114M-CN¥189MCN¥133MCN¥229M
Free cash flowCN¥464MCN¥634MCN¥318M-CN¥33.4MCN¥43.9M
Capital expenditureCN¥83.7MCN¥172MCN¥174MCN¥182MCN¥110M
Total debtCN¥5.12BCN¥5.06BCN¥5.31BCN¥5.31BCN¥4.05B

Quarterly statements and history in the cockpit →

Shu Yu Civilian Pharmacy competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%9267301408MEDPLUS266430346035900027880027279627000504600833605266603883301017.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shu Yu Civilian Pharmacy is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×2×4×926730140826643034603590002788000504600833301017.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shu Yu Civilian Pharmacy is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%301408MEDPLUS2664303460359000278800272796273148600833605266603883301017.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shu Yu Civilian Pharmacy is the large dot.

Shu Yu Civilian Pharmacy competitors and peer comparison

How Shu Yu Civilian Pharmacy compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shu Yu Civilian Pharmacy against its 14 peers (data as of 18 Nov 2026)
Measure301017.SZPeer medianRank in peer set
1-month return-16.8%-1.0%3rd lowest of 15
6-month return-11.2%-10.1%8th highest of 15
Distance from 52-week high-48.2%-35.5%5th lowest of 15
Revenue growth (TTM)+9.2%+3.9%5th highest of 15
Operating margin1.9%4.3%4th lowest of 15
EV / Sales0.8×0.7×7th most expensive of 15
Growth the price implies (Req g, 7 yrs)1.1%-7.0%4th most demanding of 13
Growth delivered (Del g)+17.4%+8.9%3rd highest of 13
Hurdle (Req g minus delivered)-16.3 pp-20.0 pp6th most demanding of 13
ROIC minus cost of capital+1.2 pp+2.6 pp7th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%0.8×1.1%+17.4%
Genky DrugStores 9267.TJapan$728M+3%+8%5%0.6×n/an/a
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%1.1×-7.5%+23.3%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%1.1×18.6%+17.6%
Cawachi 2664.TJapan$562M+31%-1%2%0.2×-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%0.4×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%4.2×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%0.4×-0.4%+6.5%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%0.5×-16.0%+6.5%
Ain 9627.TJapan$1.25B+2%+42%4%0.5×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%0.3×-11.5%+8.0%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%3.1×n/an/a
Shanghai No. 1 Pharmacy 600833.SSChina$299M-22%+1%-1%0.9×19.5%+6.1%
JZJ Chain Drugstore Corporation 605266.SSChina$293M-35%-5%0%0.7×-9.9%+14.8%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%0.8×-10.7%+9.7%

Questions

Which companies are Shu Yu Civilian Pharmacy's closest peers?
The cockpit's peer set: Genky DrugStores (9267.T), Anhui Huaren Health Pharmaceutical (301408.SZ), MedPlus Health Services (MEDPLUS.NS), Cawachi (2664.T), Qol (3034.T), Beijing Konruns Pharmaceutical (603590.SS), Luyan Pharma (002788.SZ), Yixintang Pharmaceutical (002727.SZ).
Is Shu Yu Civilian Pharmacy expensive compared with its peers?
On ev / sales it trades at 0.8× against a peer median of 0.7×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Shu Yu Civilian Pharmacy stock performed?
Over six months to 18 Nov 2026 the shares returned -11.2% against -10.1% for the median peer; over one year -4.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.